经皮消融治疗肝细胞癌:单中心7年长期结局分析
该单中心回顾性研究纳入2015至2022年接受经皮消融的419例肝细胞癌患者,多数为微波消融(98.3%),平均肿瘤大小2.3 cm。消融后6个月内影像学评估完全缓解率96.2%,1、3、5年生存率分别为85.9%、67.8%、63.2%,功能状态维持或改善比例高,提示消融安全有效。
要点
- 消融后6个月内影像评估完全缓解率达96.2%,提示局部控制良好。
- 1、3、5年生存率分别为85.9%、67.8%、63.2%,长期生存可观。
- 91.4%和83.3%的患者在6个月和12个月时ECOG功能状态维持或改善。
局限性
- 单中心回顾性设计,可能存在选择偏倚。
- 未报告无进展生存期的置信区间及并发症具体数据。
- 未与其他治疗方式直接比较。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: The objective of this study is to examine the safety and efficacy of ablative therapy for hepatocellular carcinoma (HCC).
METHODS: A retrospective review of 419 consecutive patients diagnosed with HCC, treated with percutaneous ablation at a tertiary academic medical center from June 2015 to June 2022, was conducted. Data evaluated included demographics, disease and tumor burden scores, and functional status. Procedural outcomes included procedural course, complication rates, biochemical and radiologic response, survival, and functional status.
RESULTS: A total of 419 patients, including 313 males (74.7%) and 106 females (25.3%) with a mean age of 63.8 ± 6.64 years, made up the study cohort. 120 patients (28.6%) presented with solitary lesions and 299 patients (71.4%) had multifocal involvement, with a mean tumor size of 2.3 ± 0.92 cm. A majority of the interventions performed were microwave ablations (n = 413, 98.3%), with 6 radiofrequency ablations (1.4%). Treatment response was radiographically assessed up to 6 months post-ablation and graded as complete response (96.2%), partial response (2.6%), stable disease (0%), and progressive disease (1.2%). 97 (23.2%) of the treated patients went on to receive liver transplant. The average progression-free survival in the study population was 24 months with a survival of 85.9% (n = 360), 67.8% (n = 284), and 63.2% (n = 265) at 1 year, 3 years, and 5 years respectively. Functional outcomes, as defined by ECOG scores, were maintained or improved in 383 patients (91.4%) and 349 patients (83.3%) at 6 months and 12 months respectively.
CONCLUSIONS: This large institutional experience demonstrated safety and efficacy of ablation therapies for treatment of HCC with promising tumor response rates and enduring clinical outcomes including prolonged survival and preserved functional status.
引用
- Domini, Makary. Single-center analysis of percutaneous ablation in the treatment of hepatocellular carcinoma: long-term outcomes of a 7-year experience. Abdom Radiol (NY). 2023. PMID: 36717404. doi:10.1007/s00261-023-03819-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。